Prevention of allergy by virus‐like nanoparticles (VNP) delivering shielded versions of major allergens in a humanized murine allergy model DOI Creative Commons
Bernhard Kratzer,

Cordula Köhler,

Sandra Höfer

et al.

Allergy, Journal Year: 2018, Volume and Issue: 74(2), P. 246 - 260

Published: July 23, 2018

In high-risk populations, allergen-specific prophylaxis could protect from sensitization and subsequent development of allergic disease. However, such treatment might itself induce allergies, thus requiring hypoallergenic vaccine formulations. We here characterized the preventive potential virus-like nanoparticles (VNP) expressing surface-exposed or shielded allergens.Full-length major mugwort pollen allergen Art v 1 was selectively targeted either to surface inner side lipid bilayer envelope VNP. Upon biochemical immunological analysis, their determined in a humanized mouse model allergy.Virus-like version 1, contrast those were as they hardly induced degranulation rat basophil leukemia cells sensitized with 1-specific human IgE. Both VNP versions proliferation cytokine production T vitro. intranasal application mice, but not antibodies, including Notably, allergen-protected mice extract. Protection associated Th1/Treg-dominated response, increased Foxp3+ Treg numbers lungs, reduced lung resistance when compared treated empty particles.Virus-like represent novel versatile platform for vivo delivery allergens target prevent allergies without inducing reactions sensitization.

Language: Английский

The role of allergen‐specific IgE, IgG and IgA in allergic disease DOI Creative Commons
Mohamed H. Shamji, Rudolf Valenta, Theodore S. Jardetzky

et al.

Allergy, Journal Year: 2021, Volume and Issue: 76(12), P. 3627 - 3641

Published: May 17, 2021

Immunoglobulin E (IgE)-mediated allergy is the most common hypersensitivity disease affecting more than 30% of population. Exposure to even minute quantities allergens can lead production IgE antibodies in atopic individuals. This termed allergic sensitization, which occurs mainly early childhood. Allergen-specific then binds high (FcεRI) and low-affinity receptors (FcεRII, also called CD23) for on effector cells antigen-presenting cells. Subsequent repeated allergen exposure increases allergen-specific levels and, by receptor cross-linking, triggers immediate release inflammatory mediators from mast basophils whereas IgE-facilitated presentation perpetuates T cell-mediated inflammation. Due engagement are highly selective IgE, tiny amounts induce massive Naturally occurring IgG IgA usually recognize different epitopes compared with do not efficiently interfere allergen-induced However, these important be induced immunotherapy or passive immunization. These will competition binding prevent responses. Similarly, anti-IgE treatment does same preventing its basophils. Here, we review complex interplay corresponding cell diseases relevance diagnosis, prevention allergy.

Language: Английский

Citations

206
Microneedles for painless transdermal immunotherapeutic applications DOI
Hamed Amani, Mohammad‐Ali Shahbazi, Carmine D’Amico

et al.

Journal of Controlled Release, Journal Year: 2020, Volume and Issue: 330, P. 185 - 217

Published: Dec. 17, 2020

Language: Английский

Citations

180
Functions and regulation of T cell-derived interleukin-10 DOI
Christian Neumann, Alexander Scheffold, Sascha Rutz

et al.

Seminars in Immunology, Journal Year: 2019, Volume and Issue: 44, P. 101344 - 101344

Published: Aug. 1, 2019

Language: Английский

Citations

161
Allergic Rhinitis: A Clinical and Pathophysiological Overview DOI Creative Commons
Siti Muhamad Nur Husna, Hern‐Tze Tina Tan, Norasnieda Md Shukri

et al.

Frontiers in Medicine, Journal Year: 2022, Volume and Issue: 9

Published: April 7, 2022

Allergic rhinitis (AR) represents a global health concern where it affects approximately 400 million people worldwide. The prevalence of AR has increased over the years along with urbanization and environmental pollutants thought to be some leading causes disease. Understanding pathophysiology is crucial in development novel therapies treat this incurable disease that often comorbids other airway diseases. Hence mini review, we summarize well-established yet vital aspects AR. These include epidemiology, clinical laboratory diagnostic criteria, pediatrics, AR, Th2 responses disease, as well pharmacological immunomodulating for patients.

Language: Английский

Citations

149
A WAO — ARIA — GA2LEN consensus document on molecular-based allergy diagnosis (PAMD@): Update 2020 DOI Creative Commons
Ignacio J. Ansotegui,

Giovanni Melioli,

Giorgio Walter Canonica

et al.

World Allergy Organization Journal, Journal Year: 2020, Volume and Issue: 13(2), P. 100091 - 100091

Published: Feb. 1, 2020

Abstract

Precision allergy molecular diagnostic applications (PAMD@) is increasingly entering routine care. Currently, more than 130 allergenic molecules from 50 sources are commercially available for in vitro specific immunoglobulin E (sIgE) testing. Since the last publication of this consensus document, a great deal new information has become regarding topic, with over 100 publications in year alone. It thus seems quite reasonable to publish an update. imperative that clinicians and immunologists specifically trained allergology keep abreast rapidly evolving evidence PAMD@. PAMD@ may initially appear complex interpret; however, increasing experience, gained provides relevant allergist. This especially true food allergy, Hymenoptera selection allergen immunotherapy. Nevertheless, all sIgE tests, including PAMD@, should be evaluated within framework patient's clinical history, because sensitization does not necessarily imply allergies.

Language: Английский

Citations

118
Allergen Extracts for In Vivo Diagnosis and Treatment of Allergy: Is There a Future? DOI Creative Commons
Rudolf Valenta, А. В. Караулов,

Verena Niederberger

et al.

The Journal of Allergy and Clinical Immunology In Practice, Journal Year: 2018, Volume and Issue: 6(6), P. 1845 - 1855.e2

Published: Oct. 5, 2018

Today, in vivo allergy diagnosis and allergen-specific immunotherapy (AIT) are still based on allergen extracts obtained from natural sources. Several studies analyzing the composition of have shown severe problems regarding their quality such as presence undefined nonallergenic materials, contaminants well high variabilities contents biological activity individual allergens. Despite increasing availability sophisticated analytical technologies, these cannot be overcome because they inherent to sources methods extract production. For vitro related been largely by implementation recombinant molecules that defined purity activity. However, no advances made for preparations used therapy. No clinical performed available document safety, sensitivity, specificity products. Only very few therapeutic state-of-the-art provide evidence safety efficacy. In this article, we discuss inconsistent products share our observations most AIT do not meet international standards medicinal We argue a replacement recombinantly produced and/or mixtures thereof may only way guarantee supply clinicians with treatment allergic patients future.

Language: Английский

Citations

107
Past, present, and future of allergen immunotherapy vaccines DOI Creative Commons
Yulia Dorofeeva, I.P. Shilovskiy, Inna Tulaeva

et al.

Allergy, Journal Year: 2020, Volume and Issue: 76(1), P. 131 - 149

Published: April 6, 2020

Allergen-specific immunotherapy (AIT) is an allergen-specific form of treatment for patients suffering from immunoglobulin E (IgE)-associated allergy; the most common and important immunologically mediated hypersensitivity disease. AIT based on administration disease-causing allergen with goal to induce a protective immunity consisting blocking IgG antibodies alterations cellular immune response so that patient can tolerate contact. Major advantages over all other existing treatments allergy are induces long-lasting protection prevents progression disease severe manifestations. cost effective because it uses patient´s own system potentially be used as preventive treatment. However, broad application limited by mainly technical issues such quality preparations risk inducing side effects which results in extremely cumbersome schedules reducing compliance. In this article we review progress made its beginning provide overview state art, needs further development, possible solutions available through molecular allergology. Finally, consider visions development towards prophylactic application.

Language: Английский

Citations

100
Molecular diagnosis for allergen immunotherapy DOI Open Access
Paolo Maria Matricardi, Stephanie Dramburg, Ekaterina Potapova

et al.

Journal of Allergy and Clinical Immunology, Journal Year: 2019, Volume and Issue: 143(3), P. 831 - 843

Published: March 1, 2019

Language: Английский

Citations

86
Egg Allergy: Diagnosis and Immunotherapy DOI Open Access
Dulashi Withanage Dona, Cenk Suphioglu

International Journal of Molecular Sciences, Journal Year: 2020, Volume and Issue: 21(14), P. 5010 - 5010

Published: July 16, 2020

Hypersensitivity or an allergy to chicken egg proteins is a predominant symptomatic condition affecting 1 in 20 children Australia; however, effective form of therapy has not yet been found. This occurs as the immune system allergic individual overreacts when contact with allergens (egg proteins), triggering complex response. The subsequent instantaneous inflammatory response characterized by excessive production immunoglobulin E (IgE) antibody against allergen, T-cell mediators and inflammation. Current allergen-specific approaches diagnosis treatment lack consistency therefore pose safety concerns among anaphylactic patients. Immunotherapy thus far found be most efficient way treat relieve symptoms, this includes oral immunotherapy (OIT) sublingual (SLIT). A major limitation immunotherapy, difficulty preparing safe extracts from natural allergen sources. Advances molecular techniques allow for standardized recombinant hypoallergenic variants targeting IgE-binding epitopes responsible clinical symptoms. Site-directed mutagenesis can performed create such hypoallergens their potential use future methods providing feasible therapeutic approach target allergies safely.

Language: Английский

Citations

75
Molecular profiling of allergen-specific antibody responses may enhance success of specific immunotherapy DOI Creative Commons

Azahara Rodríguez-Domínguez,

Margot Berings, Alexander Rohrbach

et al.

Journal of Allergy and Clinical Immunology, Journal Year: 2020, Volume and Issue: 146(5), P. 1097 - 1108

Published: April 13, 2020

House dust mites (HDMs) are among the most important allergen sources containing many different allergenic molecules. Analysis of patients from a double-blind, placebo-controlled allergen-specific immunotherapy (AIT) study indicated that may benefit AIT to extents depending on their molecular sensitization profiles.Our aim was investigate in real-life setting whether stratification with HDM allergy according analysis enhance success.Serum and nasal secretion samples (n = 24) (at baseline, 7, 15, 33, 52 weeks) who had received 1 year treatment well-defined subcutaneous form (Alutard SQ 510) were tested for IgE IgG reactivity 15 microarrayed molecules ImmunoCAP Immuno-solid-phase Allergen Chip technology. subclass levels allergens peptides determined by ELISA, blocking assessed basophil activation. In vitro parameters related reduction symptoms combined symptom medication score visual analog scale score.Alutard 510 induced protective mainly against Dermatophagoides pteronyssinus (Der p) Der p 2 lesser extent 23, but not other such as 5, 21, showing better clinical efficacy sensitized only and/or compared having additional specificities.Stratification profiles monitoring AIT-induced responses success AIT.

Language: Английский

Citations

73